BioSpace News Archive

BioCapital

United Therapeutics Corporation To Present At Oppenheimer 28th Annual Healthcare Conference

United Therapeutics Corporation announced that Martine Rothblatt, Ph.D., Chairman and Chief Executive Officer of United Therapeutics, will provide an overview and update on the company’s business at the Oppenheimer 28th Annual Healthcare Conference in New York City.

March 14, 2018
·
1 min read
Business

TapImmune to Present at Two Upcoming Investor Conferences

TapImmune Inc. announced that its President and CEO, Peter Hoang, will participate in a panel discussion and give a company presentation at the Sachs BioCapital USA Forum, held March 21st, 2018.

March 14, 2018
·
1 min read
Business

Flagship Pioneering Launches Foghorn Therapeutics With Initial Capital Commitment of $50 Million

Company’s Proprietary Gene Traffic Control™ product platform provides a new way to think about treating disease.

March 14, 2018
·
5 min read
Business

ProMIS Neurosciences Announces Fiscal Year 2017 Annual Results

ProMIS Neurosciences, Inc. a biotechnology company focused on the discovery and development of precision treatments for neurodegenerative diseases, today announced its operational and financial results for the year ended December 31, 2017.

March 14, 2018
·
6 min read
Business

Arena Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full-Year 2017 Financial Results

“We’ve made significant progress in 2017, achieving the clinical and corporate objectives we set forth as a new team,” said Amit D. Munshi, president and CEO.

March 14, 2018
·
17 min read
BioMidwest

On Target Laboratories Raises Additional Capital from H.I.G. BioHealth Partners, Elevate Ventures and Helsinn

These recent raises bring the total financing round close to $44 million.

March 14, 2018
·
5 min read
Pharm Country

Bridge Medicines Accepts Novel Small Molecule Targeting Basal Cell Carcinoma As First Drug Candidate for Development

Project Originated at Rockefeller University and Graduated From Tri-Institutional Therapeutics Discovery Institute

March 14, 2018
·
4 min read
FDA

Amneal Gains Approval for Erythromycin Tablets USP

Amneal Pharmaceuticals has received FDA approval for Erythromycin Tablets USP, 250 mg and 500 mg strengths.

March 14, 2018
·
2 min read
Business

BioSpecifics Technologies Corp. Reports Fourth Quarter and Full Year 2017 Financial Results

BioSpecifics reported net income of $2.6 million for the fourth quarter ended December 31, 2017.

March 14, 2018
·
16 min read
Drug Development

TARIS® Initiates Dosing of TAR-200 (GemRIS™) in Muscle-Invasive Bladder Cancer Patients Unfit for Curative Intent Therapy

TARIS announced today that it has initiated dosing in a clinical trial of TAR-200 (GemRIS™) in patients with Muscle Invasive Bladder Cancer (MIBC) who are unfit for therapy with curative intent.

March 14, 2018
·
3 min read